ATE329596T1 - Phthalazinderivate zur behandlung von entzündlicher erkrankungen - Google Patents

Phthalazinderivate zur behandlung von entzündlicher erkrankungen

Info

Publication number
ATE329596T1
ATE329596T1 AT00920604T AT00920604T ATE329596T1 AT E329596 T1 ATE329596 T1 AT E329596T1 AT 00920604 T AT00920604 T AT 00920604T AT 00920604 T AT00920604 T AT 00920604T AT E329596 T1 ATE329596 T1 AT E329596T1
Authority
AT
Austria
Prior art keywords
treatment
disease
phthalazine derivatives
inflammatory diseases
preparation
Prior art date
Application number
AT00920604T
Other languages
English (en)
Inventor
Guido Bold
King Janet Dawson
Joerg Frei
Richard Heng
Paul William Manley
Bernhard Wietfeld
Jeanette Marjorie Wood
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9916064.0A external-priority patent/GB9916064D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE329596T1 publication Critical patent/ATE329596T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00920604T 1999-03-30 2000-03-28 Phthalazinderivate zur behandlung von entzündlicher erkrankungen ATE329596T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH60399 1999-03-30
GBGB9916064.0A GB9916064D0 (en) 1999-07-08 1999-07-08 Organic compounds

Publications (1)

Publication Number Publication Date
ATE329596T1 true ATE329596T1 (de) 2006-07-15

Family

ID=25685089

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00920604T ATE329596T1 (de) 1999-03-30 2000-03-28 Phthalazinderivate zur behandlung von entzündlicher erkrankungen

Country Status (13)

Country Link
US (4) US6686347B2 (de)
EP (1) EP1165085B1 (de)
JP (1) JP4673977B2 (de)
CN (2) CN1660840A (de)
AT (1) ATE329596T1 (de)
AU (1) AU766081B2 (de)
BR (1) BR0009507A (de)
CA (1) CA2366857C (de)
DE (1) DE60028740T2 (de)
ES (1) ES2265929T3 (de)
NO (3) NO320849B1 (de)
PT (1) PT1165085E (de)
WO (1) WO2000059509A1 (de)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
EA010183B1 (ru) 1997-05-14 2008-06-30 Атеродженикс, Инк. Сложный моноэфир янтарной кислоты и пробукола для лечения сердечно-сосудистых и воспалительных заболеваний
EP1165085B1 (de) * 1999-03-30 2006-06-14 Novartis AG Phthalazinderivate zur behandlung von entzündlicher erkrankungen
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
CO5200835A1 (es) * 1999-09-28 2002-09-27 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
AU2001296871A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1339458B1 (de) * 2000-11-22 2007-08-15 Novartis AG Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
WO2002060492A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
PT2269603E (pt) 2001-02-19 2015-09-09 Novartis Ag Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
GB0111078D0 (en) * 2001-05-04 2001-06-27 Novartis Ag Organic compounds
PT1392313E (pt) 2001-05-16 2007-07-17 Novartis Ag Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20040266779A1 (en) * 2001-09-27 2004-12-30 Anderson Kenneth C. Use of c-kit inhibitors for the treatment of myeloma
US7819875B2 (en) * 2002-02-08 2010-10-26 Gursharan Singh Chana Surgical devices and methods of use
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
PL372103A1 (en) * 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
PL374967A1 (en) 2002-08-02 2005-11-14 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
EP1545534B1 (de) * 2002-09-24 2007-04-18 Novartis AG Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
EP1554015A1 (de) * 2002-10-10 2005-07-20 Novartis AG Behandlung von amm
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
JP2006512360A (ja) * 2002-12-20 2006-04-13 ダナ−ファーバー　キャンサー　インスティテュート，インコーポレイテッド ＶｏｎＨｉｐｐｅｌ−Ｌｉｎｄａｕ病の処置
ITMI20022739A1 (it) * 2002-12-23 2004-06-24 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
RS53476B (sr) 2003-07-18 2014-12-31 Amgen Fremont Inc. Sredstva za specifično vezivanje faktora rasta hepatocita
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
JP5149009B2 (ja) * 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
AR051093A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2029138A1 (de) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazolderivate als humane stearoyl-coa desaturasehemmer
KR20080054417A (ko) 2005-09-27 2008-06-17 노파르티스 아게 카르복시아민 화합물 및 ｈｄａｃ 의존성 질환의 치료에있어서의 그의 용도
CN101316597B (zh) 2005-11-03 2013-04-17 顶点医药品公司 用作激酶抑制剂的氨基嘧啶
AU2006314444C1 (en) 2005-11-21 2018-01-04 Novartis Ag Neuroendocrine tumor treatment using mTOR inhibitors
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
JP2009526050A (ja) 2006-02-10 2009-07-16 アムジエン・インコーポレーテツド Ａｍｇ７０６の水和物形態
CN101415409B (zh) 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
EP2026800A1 (de) 2006-05-09 2009-02-25 Novartis AG Kombination aus einem eisenchelatbildner und einem anti-neoplastischen mittel und ihre verwendung
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
US8044041B2 (en) * 2006-11-15 2011-10-25 Forest Laboratories Holdings Limited Phthalazine derivatives as inhibitors of protein kinase
AU2007338792B2 (en) 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
EP2118069B1 (de) 2007-01-09 2014-01-01 Amgen Inc. Bis-aryl amid-derivate zur krebsbehandlung
EP2491923A3 (de) 2007-02-15 2012-12-26 Novartis AG Kombinationen therapeutischer Wirkstoffe zur Krebsbehandlung
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
PE20090188A1 (es) * 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
EP2139320A4 (de) 2007-03-26 2010-09-08 Salutria Pharmaceuticals Llc Verfahren und zusammensetzungen von probucol-derivaten für die behandlung von diabetes
CN101790532B (zh) 2007-07-31 2013-11-20 沃泰克斯药物股份有限公司 5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法
TWI595005B (zh) 2007-08-21 2017-08-11 安健股份有限公司 人類ｃ－ｆｍｓ抗原結合蛋白質
EP2260020B1 (de) 2008-03-26 2014-07-23 Novartis AG Auf hydroxamat basierende hemmer von deacetylasen b
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EP2344161B1 (de) 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Kombinationen eines liposomalen wasserlöslichen camptothecins mit cetuximab oder bevacizumab
CN102256941A (zh) 2008-12-18 2011-11-23 诺瓦提斯公司 新的盐
WO2010071794A1 (en) 2008-12-18 2010-06-24 Novartis Ag New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
PL2676953T3 (pl) 2008-12-18 2017-09-29 Novartis Ag Sól hemifumaranowa kwasu 1-[4-[1-(4-cykloheksylo-3-trifluorometylobenzyloksyimino)-etylo]-2-etylobenzylo]-azetydyno-3-karboksylowego
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
WO2010091257A1 (en) 2009-02-06 2010-08-12 Bach Pharma, Inc. Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them
UA105794C2 (uk) 2009-06-26 2014-06-25 Новартіс Аг 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
HRP20190016T1 (hr) 2009-08-17 2019-03-08 Intellikine, Llc Heterociklički spojevi i njihova upotreba
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
EA201200321A1 (ru) 2009-08-26 2012-09-28 Новартис Аг Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
EA201200471A1 (ru) 2009-09-10 2012-10-30 Новартис Аг Простые эфирные производные бициклических гетероарилов
JP5466767B2 (ja) 2009-11-04 2014-04-09 ノバルティス アーゲー Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体
US20120289501A1 (en) 2009-11-25 2012-11-15 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
ES2484171T3 (es) 2009-12-08 2014-08-11 Novartis Ag Derivados de sulfonamidas heterocíclicas
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP2582680A1 (de) 2010-06-17 2013-04-24 Novartis AG Biphenyl-substituierte 1,3-dihydro-benzoimidazol-2-ylidenamidderivate
US20130085161A1 (en) 2010-06-17 2013-04-04 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
US20130338152A1 (en) 2011-03-08 2013-12-19 Irm Llc Fluorophenyl bicyclic heteroaryl compounds
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
EA023064B1 (ru) 2011-04-28 2016-04-29 Новартис Аг ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
MX2013014398A (es) 2011-06-09 2014-03-21 Novartis Ag Derivados de sulfonamida heterociclicos.
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
EP2785717B1 (de) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidinverbindungen
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EA201491264A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
AU2012355624A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355619A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
EP2948453B1 (de) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinonverbindungen als inhibitoren der p53/mdm2-interaktion
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
EP3242934B1 (de) 2015-01-08 2021-08-18 The Board of Trustees of the Leland Stanford Junior University Faktoren und zellen zur bereitstellung der induktion von knochen, knochenmark und knorpel
EP3558955B1 (de) 2016-12-22 2021-08-11 Amgen Inc. Benzisothiazol-, isothiazolo[3,4-b]pyridin-, quinazolin-, phthalazin-, pyrido[2,3-d]pyridazin- und pyrido[2,3-d]pyrimidin-derivate als kras g12c inhibitoren zur behandlung von lungen-, bauchspeicheldrüsen- oder darmkrebs
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
EP3679040B1 (de) 2017-09-08 2022-08-03 Amgen Inc. Inhibitoren von kras g12c und verfahren zur verwendung davon
EP3697425A1 (de) 2017-10-18 2020-08-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Verfahren und verbindungen zur verbesserten immunzelltherapie
WO2019119486A1 (zh) 2017-12-21 2019-06-27 中国科学院合肥物质科学研究院 一类嘧啶类衍生物激酶抑制剂
AU2019262589B2 (en) 2018-05-04 2022-07-07 Amgen Inc. KRAS G12C inhibitors and methods of using the same
ES2995514T3 (en) 2018-05-04 2025-02-10 Amgen Inc Kras g12c inhibitors and methods of using the same
MX2020011907A (es) 2018-05-10 2021-01-29 Amgen Inc Inhibidores de kras g12c para el tratamiento de cancer.
ES2938987T3 (es) 2018-06-01 2023-04-18 Amgen Inc Inhibidores de KRAS G12c y métodos de uso de los mismos
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
CA3100390A1 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
CA3123871A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
JP7676308B2 (ja) 2018-12-20 2025-05-14 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
MX2021010323A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos bicíclicos de heterociclilo y usos de este.
EP3738593A1 (de) 2019-05-14 2020-11-18 Amgen, Inc Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
PH12021552922A1 (en) 2019-05-21 2022-04-04 Amgen Inc Solid state forms
JP7756070B2 (ja) 2019-08-02 2025-10-17 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤としてのピリジン誘導体
JP7640521B2 (ja) 2019-08-02 2025-03-05 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
MX2022001295A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
AU2020324406A1 (en) 2019-08-02 2022-03-17 Amgen Inc. KIF18A inhibitors
AU2020369569A1 (en) 2019-10-24 2022-04-14 Amgen Inc. Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
CA3159561A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
AU2020379731A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
MX2022005525A (es) 2019-11-08 2022-06-08 Revolution Medicines Inc Compuestos de heteroarilo bicíclicos y usos de estos.
AR120456A1 (es) 2019-11-14 2022-02-16 Amgen Inc Síntesis mejorada del compuesto inhibidor de g12c de kras
EP4058465A1 (de) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4-antagonistenpeptide
US12466825B2 (en) 2019-11-14 2025-11-11 Amgen Inc. Synthesis of KRAS G12C inhibitor compound
EP4065231A1 (de) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Kovalente ras-inhibitoren und verwendungen davon
MX2022008305A (es) 2020-01-07 2022-08-08 Revolution Medicines Inc Dosificacion de inhibidores de shp2 y metodos de tratamiento del cancer.
TW202214253A (zh) 2020-06-18 2022-04-16 美商銳新醫藥公司 延遲、預防及治療對ｒａｓ抑制劑之後天抗性之方法
CN112661696A (zh) * 2020-06-29 2021-04-16 华东理工大学 多芳香基取代的甲醇的绿色合成方法
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
PE20231207A1 (es) 2020-09-15 2023-08-17 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer
CN112110790B (zh) * 2020-09-28 2023-06-23 台州臻挚生物科技有限公司 一种3,5-二卤三氟甲苯及3`-氯-5`-(三氟甲基)苯基三氟乙酮的制备方法
WO2022061918A1 (zh) * 2020-09-28 2022-03-31 杭州臻挚生物科技有限公司 一种3,5-二卤三氟甲苯及3'-氯-5'-(三氟甲基)苯基三氟乙酮的制备方法
CN114685395A (zh) * 2020-12-29 2022-07-01 浙江大学 一种2,3-二氢苯并[d]异噻唑类化合物及其应用
US20240174651A1 (en) * 2021-01-28 2024-05-30 The Scripps Research Institute Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
PE20240089A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer
MX2023013085A (es) 2021-05-05 2023-11-16 Revolution Medicines Inc Inhibidores de ras.
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
JP2025509217A (ja) 2022-03-07 2025-04-11 アムジエン・インコーポレーテツド ４－メチル－２－プロパン－２－イル－ピリジン－３－カルボニトリルを調製するための方法
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
CN120504682A (zh) 2022-06-10 2025-08-19 锐新医药公司 大环ras抑制剂
IL320217A (en) 2022-10-14 2025-06-01 Black Diamond Therapeutics Inc Methods for treating cancer using isoquinoline or 6-azaquinoline derivatives
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
AU2024253668A1 (en) 2023-04-07 2025-11-13 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
US20240352038A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2960504A (en) * 1957-05-07 1960-11-15 Ciba Pharm Prod Inc 1-hydrazino, 4-pyridyl methyl-phthalazines
BE567431A (de) 1957-05-07
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US4665181A (en) * 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
JPH01261386A (ja) * 1988-04-11 1989-10-18 Nisshin Flour Milling Co Ltd 新規な２―ピリジルメチルチオ誘導体及びそれを含有する抗潰瘍剤
NZ290952A (en) * 1994-08-09 1998-05-27 Eisai Co Ltd Phthalazine derivatives optionally substituted in position-1 by (generally benzyl) amino groups
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
FR2752734B1 (fr) * 1996-09-02 1998-11-06 Cird Galderma Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
JPH10218791A (ja) * 1997-01-31 1998-08-18 Toagosei Co Ltd 慢性関節リウマチ治療薬
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
PT1105136E (pt) * 1998-08-13 2007-12-03 Novartis Ag Método para tratar doenças oculares neovasculares
EP1165085B1 (de) * 1999-03-30 2006-06-14 Novartis AG Phthalazinderivate zur behandlung von entzündlicher erkrankungen

Also Published As

Publication number Publication date
NO20052893L (no) 2001-10-19
JP2002541108A (ja) 2002-12-03
NO20014655L (no) 2001-10-19
BR0009507A (pt) 2002-01-15
NO20014655D0 (no) 2001-09-25
US20040142934A1 (en) 2004-07-22
NO320849B1 (no) 2006-02-06
NO20052893D0 (no) 2005-06-14
WO2000059509A1 (en) 2000-10-12
EP1165085B1 (de) 2006-06-14
US20030013718A1 (en) 2003-01-16
CN1367695A (zh) 2002-09-04
US6911440B2 (en) 2005-06-28
ES2265929T3 (es) 2007-03-01
AU4112500A (en) 2000-10-23
US20050176711A1 (en) 2005-08-11
NO20054048L (no) 2001-10-19
CN1221262C (zh) 2005-10-05
AU766081B2 (en) 2003-10-09
DE60028740D1 (de) 2006-07-27
EP1165085A1 (de) 2002-01-02
CA2366857C (en) 2010-12-14
US7329660B2 (en) 2008-02-12
US6686347B2 (en) 2004-02-03
CN1660840A (zh) 2005-08-31
CA2366857A1 (en) 2000-10-12
JP4673977B2 (ja) 2011-04-20
DE60028740T2 (de) 2007-05-24
US20060217388A1 (en) 2006-09-28
PT1165085E (pt) 2006-10-31

Similar Documents

Publication Publication Date Title
ATE329596T1 (de) Phthalazinderivate zur behandlung von entzündlicher erkrankungen
MA32167B1 (fr) Dérivés d'imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met
ATE405564T1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
EA200900388A1 (ru) Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
NO20063758L (no) Pyrazolo[1,5-A]pyrimidin-7-yl-amin derivater for anvendelse i behandling av proteinkinase avhengige sykdommer
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
EA200870218A1 (ru) Замещенные имидазольные производные, композиции и способы применения в качестве ингибиторов ртразы
ATE365550T1 (de) Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
EA200600209A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
PE20030714A1 (es) Derivados de amidas de acido antranilico como inhibidores del receptor de tirosina quinasa vegf
DOP2005000014A (es) Derivados 1h-tieno[2, 3-c] pirazol utiles como inhibidores de quinasa
DE69917074D1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
KR102023748B1 (ko) 순수한 5-ht6 수용체 길항제 및 nmda 수용체 길항제의 조합물
DE69912304D1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
EP4045506A4 (de) 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridin-3-yl)pyrimidin-2-amin-derivate zum behandeln proliferativer krankheiten und zustände
HUP0303253A2 (hu) Aril-karbamát-származékok, eljárás előállításukra és alkalmazásuk
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165085

Country of ref document: EP